| Expression pattern: |
UP |
| Associated gene: |
galectin-1 (Gal-1), Gal-1 messenger RNA, p-AKT, p-ERK1/2, AKT, ERK1/2 |
| Associated microRNA: |
miR-22-3p |
| Biological function: |
Promotes NSCLC cell invasion and proliferation; acts as an oncogene in NSCLC progression. |
| Molecular mechanism: |
circFGFR3 functions as a ceRNA by sponging miR-22-3p, upregulating Gal-1 expression and activating AKT and ERK1/2 signaling. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (promotes); invasion (promotes); AKT (promotes); ERK (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Luciferase Reporter Assay; Western Blot; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circFGFR3 expression correlates with poor clinical outcomes, bad prognosis, larger tumors, tumor stage, lymph node metastasis, tumor size, and differentiation in NSCLC patients; circFGFR3 may serve as a prognostic biomarker and therapeutic target. |
| Description: |
circFGFR3 is up-regulated in human NSCLC tissues and is associated with poor clinical outcomes. Functionally, circFGFR3 promotes NSCLC cell proliferation and invasion. Mechanistically, it sponges miR-22-3p to increase Gal-1 expression and activate AKT and ERK1/2 signaling, suggesting a potential prognostic biomarker and therapeutic target role. |
| Confidence score: |
0.7113 |